Esquenazi Alberto, Lee Stella, Mayer Nathaniel, Garreta Roser, Patel Atul, Elovic Elie, Koelbel Stephen, Francisco Gerard, Reuter Iris
From the MossRehab Gait and Motion Analysis Laboratory, Elkins Park, Pennsylvania (AE, SL, NM); Mutua Terrassa University Hospital, Cataluna, Spain (RG); Kansas City Bone and Joint Clinic, Overland Park, Kansas (AP); Physical Medicine and Rehabilitation, Reno, Nevada (EE); Braintree Rehabilitation Hospital, Braintree, Massachusetts (SK); University of Texas Health Science Center and TIRR Memorial Hermann, Houston, Texas (GF); and Justus-Liebig-Universität Gießen, Gießen, Hesse, Germany (IR).
Am J Phys Med Rehabil. 2017 Dec;96(12):881-888. doi: 10.1097/PHM.0000000000000781.
The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury.
A prospective, multicenter, international observational registry design was used.
Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians. Due to the limited usage of abobotulinumtoxinA Dysport and incobotulinumtoxinA Xeomin, data were reported on onabotulinumtoxinA BOTOX only. Based on physician experience, onabotulinumtoxinA doses were statistically different with larger mean doses injected by more experienced physicians in the upper limb (59.9 [39.0], P = 0.001) and in the lower limb (101.8 [69.2], P < 0.001). Treated deformities significantly differed for both upper limb and lower limb (P < 0.001). More experienced physicians showed a larger mean change in Ashworth Scale scores from baseline for the equinovarus/equinus foot and stiff knee (P = 0.001 and 0.03). Less experienced physicians showed a larger mean change in Ashworth Scale scores from baseline for the adducted thigh (P = 0.05). Less experienced physicians had statistically significant larger change in hand pain scores for clenched fist deformity treatment at follow-up compared with more experienced physicians (P = 0.01). Physician experience demonstrated a significant difference on patients reported satisfaction toward their secondary goal with higher scores for more experienced physician (P = 0.04).
This international registry provides clinical nuances of treatment based on physician clinical experience in a robust sample size.
本研究旨在报告基于医生经验的A型肉毒毒素在中风和创伤性脑损伤患者中的“真实世界”治疗模式。
采用前瞻性、多中心、国际观察性登记设计。
17名经验较丰富的医生和12名经验较少的医生对627名中风患者和132名创伤性脑损伤患者进行了评估和治疗。由于阿柏西普(Dysport)和因卡膦酸(Xeomin)的使用有限,仅报告了保妥适(BOTOX)的数据。根据医生经验,A型肉毒毒素的剂量在统计学上存在差异,经验较丰富的医生在上肢(59.9[39.0],P=0.001)和下肢(101.8[69.2],P<0.001)注射的平均剂量更大。上肢和下肢的治疗畸形存在显著差异(P<0.001)。经验较丰富的医生在内翻足/马蹄足和僵硬膝关节的Ashworth量表评分从基线的平均变化更大(P=0.001和0.03)。经验较少的医生在内收大腿的Ashworth量表评分从基线的平均变化更大(P=0.05)。与经验较丰富的医生相比,经验较少的医生在随访时握拳畸形治疗的手部疼痛评分变化在统计学上显著更大(P=0.01)。医生经验对患者报告的次要目标满意度有显著差异,经验较丰富的医生得分更高(P=0.04)。
这个国际登记处基于强大的样本量,提供了基于医生临床经验的治疗的临床细微差别。